JPH11510508A - インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法 - Google Patents

インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法

Info

Publication number
JPH11510508A
JPH11510508A JP9508479A JP50847997A JPH11510508A JP H11510508 A JPH11510508 A JP H11510508A JP 9508479 A JP9508479 A JP 9508479A JP 50847997 A JP50847997 A JP 50847997A JP H11510508 A JPH11510508 A JP H11510508A
Authority
JP
Japan
Prior art keywords
group
alkyl
substituted
patient
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9508479A
Other languages
English (en)
Japanese (ja)
Inventor
ホイツトカム，ランドル・ダブルユー
Original Assignee
ワーナー−ランバート・コンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワーナー−ランバート・コンパニー filed Critical ワーナー−ランバート・コンパニー
Publication of JPH11510508A publication Critical patent/JPH11510508A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP9508479A 1995-08-10 1996-07-29 インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法 Ceased JPH11510508A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US209895P 1995-08-10 1995-08-10
US60/002,098 1995-08-10
PCT/US1996/012430 WO1997005875A2 (en) 1995-08-10 1996-07-29 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus

Publications (1)

Publication Number Publication Date
JPH11510508A true JPH11510508A (ja) 1999-09-14

Family

ID=21699238

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9508479A Ceased JPH11510508A (ja) 1995-08-10 1996-07-29 インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法

Country Status (15)

Country Link
EP (1) EP0851757A2 (cs)
JP (1) JPH11510508A (cs)
KR (1) KR19990036290A (cs)
CN (1) CN1192683A (cs)
AU (1) AU724989B2 (cs)
BG (1) BG102235A (cs)
CA (1) CA2221241A1 (cs)
CZ (1) CZ32998A3 (cs)
EA (1) EA199800177A1 (cs)
HU (1) HUP9802543A2 (cs)
IL (1) IL122191A0 (cs)
NO (1) NO980556L (cs)
NZ (1) NZ313874A (cs)
SK (1) SK16498A3 (cs)
WO (1) WO1997005875A2 (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
GB2335597A (en) * 1998-03-27 1999-09-29 Glaxo Group Ltd Stereoisomers of Troglitazone in the Treatment of Diabetes
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
EP1087963B1 (en) 1998-06-19 2004-08-25 Chiron Corporation Inhibitors of glycogen synthase kinase 3
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
NO980556D0 (no) 1998-02-09
SK16498A3 (en) 1999-03-12
WO1997005875A3 (en) 1997-03-27
CN1192683A (zh) 1998-09-09
NO980556L (no) 1998-02-09
CZ32998A3 (cs) 1998-10-14
HUP9802543A2 (hu) 1999-07-28
WO1997005875A2 (en) 1997-02-20
NZ313874A (en) 2000-09-29
BG102235A (en) 1998-09-30
CA2221241A1 (en) 1997-02-20
AU724989B2 (en) 2000-10-05
IL122191A0 (en) 1998-04-05
KR19990036290A (ko) 1999-05-25
AU6641196A (en) 1997-03-05
EP0851757A2 (en) 1998-07-08
EA199800177A1 (ru) 1998-10-29

Similar Documents

Publication Publication Date Title
EP1248604B2 (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
US6130216A (en) Use of thiazolidinedione derivatives in the treatment of insulin resistance
US5602133A (en) Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP3544659B2 (ja) インスリン感性化剤類の高血圧治療のための使用
JP2002504137A (ja) チアゾリジンジオンおよびメトホルミンを用いる糖尿病の治療
JPH09502727A (ja) Ｎｉｄｄｍの発症を阻止又は遅延するためのチアゾリジンジオン類の用途
JP2003516310A (ja) 新規治療方法
JP2001510159A (ja) チアゾリジンジオン、インスリン分泌促進薬およびジグアニドを用いる糖尿病の治療
US5708012A (en) Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
JP2002504138A (ja) ロシグリタゾンおよびインスリンを用いる糖尿病の治療
AU731690B2 (en) Use of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)-ethoxy)benzyl) 2,4-thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes
JPH11510508A (ja) インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法
JP2001523270A (ja) チアゾリジンジオンおよびスルホニルウレアを用いる糖尿病の治療
JP2001523271A (ja) チアゾリジンジオンおよびアルファ−グルコシダーゼ阻害剤を用いる糖尿病の治療
JP2005247865A (ja) チアゾリジンジオンおよびスルホニル尿素を用いる糖尿病の治療
US6046202A (en) Use of thiazolidinedione derivatives in the treatment of insulin resistance
AU754479B2 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
MXPA97009958A (en) A method to reduce the amount of exogenous insulin administered to a patient with diabetes melitus dependent of insul
CZ20001298A3 (cs) Léčivo pro léčení hyperglykémie a farmaceutický prostředek s obsahem sensitizéru inzulinu
TW200816995A (en) Pharmaceutical composition containing insulin sensitizers
HK1014865A (en) A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
CZ20001297A3 (cs) Léčivo pro léčení hyperglykémie a farmaceutický prostředek s obsahem sensitizéru inzulinu
MXPA99008704A (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
MXPA99008411A (en) Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes
MXPA00003633A (en) Use of thiazolidinediones for the treatment of hyperglycaemia

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050322

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20050808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050913